BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Immunotope, Inc. OCPM Vaccine To Be Evaluated In Phase I Ovarian Cancer Immunotherapy Clinical Trial


10/19/2005 5:09:10 PM

DOYLESTOWN PA (PRWEB) August 19, 2005 -- Immunotope, Inc., a company developing a new generation of immunotherapeutics for the treatment of cancer and chronic infectious diseases, announced today that it has submitted an Investigational New Drug application (IND) to the US Food and Drug Administration (FDA) in collaboration with Duke University to initiate a Phase I ovarian cancer clinical trial. The trial will evaluate safety and immune response to Immunotope’s proprietary multi-peptide OPCM immunotherapeutic vaccine. This will be the first-ever cancer vaccine clinical trial to use a cocktail of novel peptide antigens to treat ovarian cancer. Immunotope’s vaccine consists of peptides derived from twelve different proteins essential to tumor survival, growth and metastasis and is designed to elicit an immune response to cancer cells that remain in the body after surgery and chemotherapy, enabling the patient’s own immune system to detect and destroy residual tumor cells and to prevent cancer recurrence. In preclinical studies, cytotoxic T cell responses were generated to all of the vaccine component peptides. In addition, the cytotoxic T cells activated against each of these peptides recognized a panel of different ovarian tumor cell lines but did not recognize normal ovary cells. Several of these peptides are also presented by MHC molecules on multiple other tumor types, indicating the broad potential to use these peptides for immunotherapy treatment of other forms of cancer.

Read at PRWEB

PRWEB
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES